2023 World Conference on Lung Cancer (Posters)-P1.27. Neoadjuvant PD-1 Blockade Plus Platinum-based Chemotherapy for EGFR-mutant NSCLC (CTONG2104): An Interim Analysis

P1.27. Neoadjuvant PD-1 Blockade Plus Platinum-based Chemotherapy for EGFR-mutant NSCLC (CTONG2104): An Interim Analysis - PDF(Abstract)

Back to course

Pdf Summary

This document is a summary of a presentation that took place during a session titled "Early-Stage Non-small Cell Lung Cancer - Innovation and New Technology" at the WCLC 2023 conference. The presentation was titled "Neoadjuvant PD-1 Blockade Plus Platinum-based Chemotherapy for EGFR-mutant NSCLC (CTONG2104): An Interim Analysis" and was conducted by a group of authors from various institutions in China.<br /><br />The presentation discussed the use of neoadjuvant therapy, specifically PD-1 blockade plus chemotherapy, for patients with early-stage non-small cell lung cancer (NSCLC) who have a mutation in the EGFR gene. The researchers conducted a phase 2 prospective trial with 35 patients and performed various analyses to assess the efficacy and safety of the treatment.<br /><br />By March 17, 2023, 13 patients had been enrolled, and 10 had completed neoadjuvant treatment and surgery. The confirmed overall response rate (ORR) was 70%, with no complete pathological response (pCR) observed. However, 30% of patients achieved a major pathological response (MPR), meeting the primary endpoint for stage I. The downstaging rate was 50%, indicating a reduction in tumor size and stage. The most common adverse event reported was neutropenia.<br /><br />The researchers also performed several analyses to assess the molecular and cellular changes associated with the treatment. They found that plasma levels of IL-8 were significantly increased in responders, while decreased in non-responders. They also observed elevated levels of early activated lymphocytes in responders after treatment.<br /><br />Overall, the study demonstrated that neoadjuvant therapy with PD-1 blockade plus chemotherapy showed superior efficacy in localized EGFR-mutant NSCLC. The researchers suggest that further analysis and investigation are needed to tailor optimal treatment modalities for these patients and to identify combination strategies for advanced NSCLC.<br /><br />In summary, this presentation reported the interim analysis of a phase 2 trial investigating neoadjuvant therapy for EGFR-mutant NSCLC. The treatment showed promising efficacy in terms of response rate and downstaging, and further analysis is needed to optimize treatment strategies for these patients.

Asset Subtitle

Chao Zhang

Meta Tag

Speaker Chao Zhang

Topic Early-Stage NSCLC: Innovation & New Technology

Keywords

Early-Stage Non-small Cell Lung Cancer

Neoadjuvant PD-1 Blockade Plus Platinum-based Chemotherapy

EGFR-mutant NSCLC (CTONG2104)

Interim Analysis

Phase 2 Prospective Trial

Overall Response Rate

Neutropenia

Localized EGFR-mutant NSCLC

Optimal Treatment Modalities

Combination Strategies